Market Research Logo

Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023

Global Microbiome Therapeutics & Diagnostics Market Analysis & Forecast to 2023

This report provides a comprehensive overview of the size of the microbiome therapeutic and diagnostic market, segmentation of the market (Gastrointestinal, Metabolic, Cancer, Neurological, Autoimmune, Skin), key players and the potential of therapies that are in clinical trials. Kelly Scientific analysis indicates that the global microbiome therapeutic and diagnostic market is worth $1.13 billion in 2018 and will grow at a CAGR of 19.03% over five years to $2.7 billion in 2023. The majority of the market will be dominated by microbiome based therapeutics, with an estimate of x%, compared to x% in microbiome diagnostics. This report describes the evolution of such a prospective market in eight chapters supported by over 82 tables and figures in 165 pages.

  • An overview of the human microbiome space that includes how the market is sub-divided into therapeutics (prebiotics, probiotics, fecal microbiota transplantation, small molecules) and diagnostics.
  • Global microbiome market, global breakdown, application breakdown and leading market players
  • Detailed account of the microbiome industry market by geography, indication and company profiles
  • Profiles, pipeline products, financial analysis and business strategy of the major companies in this space
  • Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for microbiome therapeutics and diagnostics
  • Insight into the challenges faced by stakeholders
  • Insight into the biobanking industry globally and its impact on the overall market
  • Description and data for the prevalence of disease types that are addressed by harnessing the human microbiota
  • Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
  • SWOT analysis of the global market
  • Geographical analysis and challenges within key topographies including North America, Europe, Asia/Pacific, Middle East/Africa, ROW


Chapter 1 Executive Summary
1.1 Synopsis
1.2 Objective of Report
1.3 Executive Summary
1.4 Key Questions Answered
1.5 Data Sources & Methodology
Chapter 2 Microbiome Overview
2.1 Microbiome Overview
2.2 Human Microbiome in Health and Disease
2.2.1 Cancer
2.2.2 Obesity
2.2.3 Microbiota Metabolism
2.2.3 Type 2 Diabetes Mellitus
2.2.4 Ulcerative Colitis and Crohn’s Disease
2.2.5 Clostridium Difficile Infection
2.2.6 Lactose Intolerance
2.2.7 CNS Disorders (gut brain axis)
2.2.8 Dental caries
2.2.9 Recurrent Bacterial Vaginosis and Urinary Tract Infection
2.2.10 Skin Diseases
2.2.11 Hyperoxaluria
2.2.12 Urea Cycle Disorder
2.2.13 Celiac Disease
2.2.14 Non-alcoholic Steatohepatitis (NASH)
2.2.15 Hepatic Encephalopathy
2.3 Types of Microbiome therapeutics
2.3.1 Prebiotics
2.3.2 Live BioTherapeutic Agents (Probiotics)
2.3.3 Fecal Microbiota Transplantation (FMT)
2.3.4 Small Molecules
2.4 Advances in Microbiome Research
2.4.1 MetaHIT Consortium
2.4.2 Human Microbiome Project
2.4.3 Functional Metagenomics
2.4.4 Microbiome Metabolomics
2.4.5 Identifying Microbiome Targets – Enterome EB8018 Case Study
2.5 Geographical Variation of Microbiome Composition
Chapter 3 Human Therapeutic and Diagnostic Pipeline Analysis
3.0 Synopsis
3.1 Clostridium Difficile
3.1.1 SER-109 Seres Therapeutics
3.1.2 SER-262 Seres Therapeutics
3.1.3 RBX2660 Rebiotix
3.1.4 VE303 Vedanta Biosciences
3.1.5 IMM-529 Immuron
3.1.6 MET-2 NuBiyota
3.1.7 CP101 Finch Therapeutics
3.1.8 ABI-M101 Assembly Biosciences
3.1.9 CBM-588 Osel
3.1.10 SYN-004 Synthetic Biologics
3.1.11 SYN-006 Synthetic Biologics
3.2 Ulcerative Colitis
3.2.1 FIN-524 Finch Therapeutics
3.2.2 SER-287 Seres Therapeutics
3.2.3 ABI-M201 Assembly Biosciences
3.3 Crohn’s Disease
3.3.1 ABI-M301 Assembly Biosciences
3.3.2 Thetanix 4D Pharma
3.4 Inflammatory Bowel Disease
3.4.1 SER-301 Seres Therapeutics
3.4.2 SGM-1019 Second Genome
3.4.3 Blautix 4D Pharma
3.4.4 SG-2-0776 Second Genome
3.4.5 IBD110 – Enterome/AbbVie
3.5 Immuno-Oncology
3.5.1 SER-401 Seres Therapeutics
3.5.2 Colon Polyp & Colon Cancer Test - Metabiomics
3.5.3 Colorectal Cancer (CRC) Test – Origin Sciences
3.6 Graft Versus Host Disease
3.6.1 SER-155 Seres Therapeutics
3.7 Urinary Tract Infections
3.7.1 LACTIN-V Osel
3.8 Liver Disease
3.8.1 SGM-1019 Second Genome
3.9 Phenylketoneuria
3.9.1 SYNB1020 Synlogic
3.9.2 SYNB1618 Synlogic
Chapter 4 Market Analysis & Forecast to 2023
4.0 Synopsis
4.1 Market Applications
4.1.1 Clostridium Difficile Infection
4.1.2 Inflammatory Bowel Disease
4.1.3 Ulcerative Colitis
4.1.4 Crohn’s Disease
4.1.5 Liver Disease
4.1.6 Immuno-Oncology
4.1.7 Phenylketonuria
4.2 Competitive Landscape
4.3 Market Forecast to 2023
4.3.1 Synopsis
4.3.2 Primary Research, Clinical Trial and Pipeline Trends and Analysis
4.3.3 Revenue Generation from Global Therapeutic and Diagnostic Microbiome Market 2018-2023
4.3.4 Geographical Breakdown Analysis and Forecast to 2023
4.3.5 Therapeutic and Diagnostic Submarket Breakdown By Indication
Chapter 5 Market Drivers, Trends & SWOT Analysis
5.1 Market Drivers & Trends
5.2 Market Threats & Challenges
5.3 Market Opportunities
Chapter 6 Investment and Market Deals
6.1 Public and Private Funding in the Microbiome Space
6.2 Current Market Deals
Chapter 7 Venture Capital and The Microbiome
7.0 Synopsis
7.1 How Much Investment Has been Poured into the Microbiome Space in Recent Years?
7.2 What Investment Firms are Interested in the Microbiome Space?
7.3 What Companies are Receiving Funding?
7.4 What Funding Cycles are Emerging in this Space?
Chapter 8 Major Players and Company Profiles
8.1 4D Pharma
8.2 Abbvie
8.3 Allergan
8.4 Assembly Biosciences
8.5 Bristol Myers Squibb
8.6 C3J Therapeutics
8.7 Da Volterra
8.8 Enterome
8.9 Finch Therapeutics
8.10 Immuron
8.11 Matrisys Bioscience
8.12 Merck
8.13 Osel
8.14 Pfizer
8.15 Quorum Innovations
8.16 Rebiotix
8.17 Second Genome
8.18 Seres Therapeutics
8.19 Synlogic
8.20 Synthetic Biologics
8.21 Takeda
8.22 Vedanta Biosciences
List of Exhibits
Exhibit 2.1: Microbiota Associated with Cancer Development
Exhibit 2.2: Gut Microbiota Dysbiosis and the Development of Inflammatory Immune Responses
Exhibit 2.3: Microbiota Metabolites
Exhibit 2.4: Association of Diet and Microbiota with Development of Diabetes
Exhibit 2.5: Dysbiotic Microbiota and Development of the Inflammatory Response Following C. difficile Infection
Exhibit 2.6: Host-Microbe Interactions During the Pathogenesis of Dental Caries
Exhibit 2.7: Brain Dysfunction Due to Altered Microbiota in Cirrhosis
Exhibit 2.8: Therapeutic Intervention Strategies for Microbiome Dysbiosis
Exhibit 2.9: Characteristics of Prebiotics and Probiotics
Exhibit 2.10: Probiotic Safety, Functional and Technological Usability Requirements
Exhibit 2.11: Probiotics Action within the Human Gut
Exhibit 2.12: Clinical Trials Investigating Probiotics and Obesity
Exhibit 2.13: Clinical Trials on Probiotics, Type 2 Diabetes & Non-Alcoholic Fatty Liver Disease
Exhibit 2.14: Clinical Trials Investigating Probiotics and Irritable Bowel Syndrome
Exhibit 2.15: Timeline of Fecal Microbiota Transplantation
Exhibit 2.16: Small Molecules Derived from the Human Microbiota
Exhibit 2.17: Gut IBD Microbiome Analysis by the Human Microbiome Project
Exhibit 2.18: Prediabetes Microbiome Analysis by the Human Microbiome Project
Exhibit 2.19: Pregnancy and Neonate Microbiome Analysis by the Human Microbiome Project
Exhibit 2.20: Metagenomic Analysis of the Gut Microbiome
Exhibit 2.21: Microbiome Metabolomic Applications in Health and Disease
Exhibit 2.22: Metabolites Associated with Microbial and Host metabolism
Exhibit 2.23: Enterome Platform to Study Gut Microbiome in IBD
Exhibit 2.24: Enterome EB8018 Anti-FimH Molecule for the Treatment of IBD
Exhibit 2.25: Global Microbiome Diversity by Geography and Body Area
Exhibit 3.1: Human Therapeutics Microbiome Product Pipeline
Exhibit 3.2: Number of Human Therapeutic and Diagnostic Microbiome Pipeline Products, Globally
Exhibit 3.3: Human Microbiome Therapeutics Pipeline by Drug, Company, Development Stage and Indication
Exhibit 3.4: IMM-529 by Immuron Mechanism of Action
Exhibit 4.1: Microbiome Therapeutics in Clostridium Difficile Infection
Exhibit 4.2.: Microbiome Therapeutic and Diagnostic Major Player Market Share Forecast 2023
Exhibit 4.3: Percentage of PubMed Citations by Microbiome Disease Application
Exhibit 4.4: Percentage of Clinical Trials by Microbiome Disease Application
Exhibit 4.5: Global Therapeutic and Diagnostic Microbiome Market Revenue Forecast 2018-2023
Exhibit 4.6: Current Global Therapeutic and Diagnostic Market Share of Microbiome Market
Exhibit 4.7: Global Therapeutic Microbiome Market Revenue Forecast 2018-2023
Exhibit 4.8: Global Diagnostic Microbiome Market Revenue Forecast 2018-2023
Exhibit 4.9: Geographical Microbiome Market Analysis 2018
Exhibit 4.10: Geographical Microbiome Market Forecast 2023
Exhibit 4.11: Gastrointestinal Microbiome Therapeutic Market Forecast to 2023
Exhibit 4.12: Metabolic Microbiome Therapeutic Market Forecast to 2023
Exhibit 4.13: Cancer Microbiome Therapeutic Market Forecast to 2023
Exhibit 4.14: Neurological Microbiome Therapeutic Market Forecast to 2023
Exhibit 4.15: Autoimmune Microbiome Therapeutic Market Forecast to 2023
Exhibit 4.16: Skin Microbiome Therapeutic Market Forecast to 2023
Exhibit 4.17: Gastrointestinal Microbiome Diagnostic Market Forecast to 2023
Exhibit 4.18: Metabolic Microbiome Diagnostic Market Forecast to 2023
Exhibit 4.19: Cancer Microbiome Diagnostic Market Forecast to 2023
Exhibit 4.20: Neurological Microbiome Diagnostic Market Forecast to 2023
Exhibit 4.21: Autoimmune Microbiome Diagnostic Market Forecast to 2023
Exhibit 4.22: Skin Disorders Microbiome Diagnostic Market Forecast to 2023
Exhibit 5.1: Drivers of the Microbiome Market
Exhibit 5.2: Threats and Challenges of the Microbiome Market
Exhibit 6.1: Current Market Deals in the Microbiome Space
Exhibit 7.1: Total Venture Capital Invested in the Microbiome Space, 2013-2017
Exhibit 7.2: Venture Capital Invested in the Microbiome Space by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2013-2017
Exhibit 7.3: Major Investment Firms and Investment Numbers in the Microbiome Industry by Therapeutics, Diagnostics, Agriculture and Consumer Products, 2010-2017
Exhibit 7.4: Major Microbiome Companies and Investment Received to 2017
Exhibit 7.5: Microbiome Industry Investors and Companies
Exhibit 7.6: Major Microbiome Companies and Investment Received to 2017
Exhibit 7.7: Therapeutic and Diagnostic Microbiome Investments by Funding Cycle 2010-2017
Exhibit 8.1: 4D Pharma Development Pipeline Product Portfolio
Exhibit 8.2: Assembly Biosciences Pipeline Product Pipeline
Exhibit 8.3: Assembly BioSciences R&D Expenditure 2015-2017
Exhibit 8.4: C3J Therapeutics STAMP Platform
Exhibit 8.5: C3J Therapeutics Product Pipeline
Exhibit 8.6: Da Volterra Product Pipeline Portfolio
Exhibit 8.7: Enterome Drug Discovery Platform
Exhibit 8.8: Enterome Product Pipeline
Exhibit 8.9: Osel Pipeline Product Portfolio by Clinical Stage
Exhibit 8.10: Quorum Innovations Product Pipeline Portfolio
Exhibit 8.11: Microbiota Restoration Therapy Application Areas
Exhibit 8.12: Second Genome Product Pipeline Portfolio
Exhibit 8.13: Seres Therapeutics Product Pipeline
Exhibit 8.14: Seres Therapeutics R&D Expenditure 2015-2017
Exhibit 8.15: Synlogic Product Pipeline Portfolio
Exhibit 8.16: Synthetic Biologics Product Pipeline
Exhibit 8.17: Synthetic Biologics R&D Expenditure 2015-2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report